PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Stern JM - Overall, the evidence needed to choose an antiepileptic drug (AED) wisely is incomplete, and no individual AED or group of AEDs is universally preferred as first-line therapy. Initial treatment should be based in part on the seizure-type diagnosis because the AEDs differ in their efficacy for various seizure types. The AEDs also differ in their safety, tolerability, and potential for pharmacologic interactions. These issues and the patient’s general medical history are additional factors to be used when selecting an AED. The failure of AEDs to completely control seizures should lead to consideration of epilepsy surgery, especially for patients with mesial temporal lobe epilepsy. However, there is no consensus regarding how many AEDs should be tried before the condition is deemed pharmacoresistant. Vagus nerve stimulation and the ketogenic diet are alternative treatments for patients with pharmacoresistant epilepsy who do not have epilepsy surgery or who have unsuccessful surgery.


   

Today in Clinical Guidelines...keeping you current

Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians
Annals of Internal Medicine, 10/20/09

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Thyroid, 10/30/09

From asthma severity to control: a shift in clinical practice
Primary Care Respiratory Journal, 10/19/09

Today in Neurology...keeping you current

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial
The Lancet, 10/13/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address